BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15107814)

  • 1. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma.
    Kim H; Sohn HJ; Kim SE; Kang HJ; Park S; Kim S; Kim WK; Lee JS; Suh C
    Bone Marrow Transplant; 2004 Jul; 34(1):43-9. PubMed ID: 15107814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma.
    Kim H; Sohn HJ; Kim S; Lee JS; Kim WK; Suh C
    Bone Marrow Transplant; 2006 Jun; 37(11):1037-42. PubMed ID: 16708062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
    Porrata LF; Litzow MR; Inwards DJ; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Ansell SM; Micallef IN; Markovic SN
    Bone Marrow Transplant; 2004 Feb; 33(3):291-8. PubMed ID: 14676784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
    Joao C; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Markovic SN
    Bone Marrow Transplant; 2006 May; 37(9):865-71. PubMed ID: 16532015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma.
    Gordan LN; Sugrue MW; Lynch JW; Williams KD; Khan SA; Moreb JS
    Bone Marrow Transplant; 2003 Jun; 31(11):1009-13. PubMed ID: 12774052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target.
    Katipamula R; Porrata LF; Gastineau DA; Markovic SN; Moore SB; Greiner C; Burgstaler EA; Padley DJ; Winters JL
    Bone Marrow Transplant; 2006 May; 37(9):811-7. PubMed ID: 16532018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
    Porrata LF; Ingle JN; Litzow MR; Geyer S; Markovic SN
    Bone Marrow Transplant; 2001 Nov; 28(9):865-71. PubMed ID: 11781647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
    Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation.
    Atta EH; de Azevedo AM; Maiolino A; Coelho CJ; Sarcinelli SM; de Alvarenga Máximo C; Marra VL
    Am J Hematol; 2009 Jan; 84(1):21-8. PubMed ID: 19006229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases].
    Yu YX; Shi YK; He XH; Zhou LQ; Zhou SY; Dong M; Feng FY; Sun Y
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2714-6. PubMed ID: 18167252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
    Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma.
    Tiwari D; Gao F; Hidalgo J; Adkins DR; Vij R; DiPersio JF; Khoury HJ
    Bone Marrow Transplant; 2007 Oct; 40(7):671-5. PubMed ID: 17680023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
    Porrata LF; Gertz MA; Litzow MR; Lacy MQ; Dispenzieri A; Inwards DJ; Ansell SM; Micallef IN; Gastineau DA; Elliott M; Hogan WJ; Hayman SR; Tefferi A; Markovic SN
    Clin Cancer Res; 2005 Feb; 11(3):1210-8. PubMed ID: 15709191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.
    Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):376-83. PubMed ID: 19883776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
    Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.